Disease · MONDO_0006519
Comparisons in its trials43
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 43
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group 1 vs Group 2: Overall Survival | 74 of 585 | 67 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: DFS | 114 of 585 | 113 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Local Recurrence (TLR): | 9 of 585 | 7 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Rates of Receiving Pre- or Post-operative 5FUCMT | 61 of 585 | 543 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: deaths from any cause | 74 of 585 | 67 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: serious adverse events | 10 of 585 | 7 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Pelvic R0 Resection Rate | 529 of 535 | 495 of 510 | 1,045 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Pathologic Complete Response | 117 of 535 | 124 of 510 | 1,045 | NCT01515787 | Trial comparisons |
| Arm I (Oxaliplatin, Fluorouracil, Leucovorin) vs Arm II (Oxaliplatin, Fluorouracil, Leucovorin, Bevacizumab): serious adverse events | 119 of 173 | 123 of 174 | 347 | NCT00303628 | Trial comparisons |
| Adjuvant Fluorouracil +Leucovorin vs Adjuvant FOLFOX: Death Rate | 21 of 161 | 10 of 160 | 321 | NCT00807911 | Trial comparisons |
| Adjuvant Fluorouracil +Leucovorin vs Adjuvant FOLFOX: Number of Participants With Disease Recurrence | 53 of 161 | 39 of 160 | 321 | NCT00807911 | Trial comparisons |
| Fluorouracil+Leucovorin Group vs FOLFOX Group: deaths from any cause | 21 of 161 | 10 of 160 | 321 | NCT00807911 | Trial comparisons |
| Fluorouracil+Leucovorin Group vs FOLFOX Group: serious adverse events | 0 of 149 | 0 of 146 | 295 | NCT00807911 | Trial comparisons |
| BBI608 vs Placebo: Disease Control Rate | 17 of 138 | 18 of 144 | 282 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: Number of Patients With Adverse Events | 135 of 136 | 139 of 144 | 280 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: deaths from any cause | 127 of 136 | 130 of 144 | 280 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: serious adverse events | 40 of 136 | 29 of 144 | 280 | NCT01830621 | Trial comparisons |
| Adjuvant Fluorouracil +Leucovorin vs Adjuvant FOLFOX: Number of Participants With Disease Recurrence With Pathological Stage III | 38 of 96 | 29 of 102 | 198 | NCT00807911 | Trial comparisons |
| Neoadjuvant Chemoradiation With Irinotecan vs Neoadjuvant Chemoradiation With Oxaliplatin: serious adverse events | 37 of 70 | 36 of 68 | 138 | NCT00081289 | Trial comparisons |
| Adjuvant Fluorouracil +Leucovorin vs Adjuvant FOLFOX: Number of Participants With Disease Recurrence With Pathological Stage II | 15 of 65 | 10 of 58 | 123 | NCT00807911 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006519/comparisons